Emergency Management

Emergency Management

Prevention and disruption of the COVID19 epidemic chain by rinsing the mouth and nose: Nardin19 solution is an effective inactivator in SARS-COV2 and H1N1 Influenza.

Document Type : Original Article

Authors
Nuredin Bakhtiari 1
Hamidreza Khaledi 2
Saman Hosseinkhani 3
Behzad Hemmati 4
1 department of biochemistry, faculty of biological sciences, north-tehran branches, tehran, iran
2 Department of Biology, Faculty of Basic sciences, yadegar-e-emem, islamic azad university, tehran, iran
3 Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
4 Department of Microbiology, Faculty of Basic Sciences, karaj branches, islamic azad university, alborz, iran
Abstract
The reduction of pathogenicity due to the biological structure of the virus envelope was targeted in this study. Therefore, considering the effect of the prepared solution (Nardin 19) on enveloped viruses, the aim of this study was to investigate the preventive effects of this solution on SARS co-2 virus and H1N1 flu on Vero cell line cells, respectively. And red blood cells The results of this study showed that nardin 19 solution significantly (P <0.001) reduced 2 logs of SARS Co-2 virus in approximately 2 minutes. Also, the results of hemagglutination test for H1N1 influenza virus showed that this solution was able to reduce the virus titer from 516 units to 2 units of hemagglutination in approximately 2 minutes (P <0.001). The results of cytotoxicity test for Nardin 19 solution showed that this solution had no toxicity or lethal effect on Vero cells and red blood cells in one hour. Considering that one of the main ways of penetration of SARS-2 virus and H1N1 flu is through the mouth and nose and also the significant effectiveness of nardin 19 solution in reducing the concentration of these viruses in approximately 2 minutes, according to this use Nardin 19 solution can be suggested as a suitable candidate for the prevention of Quid 19 and influenza as a mouthwash and nasal drops solution.
Keywords
Increase resilience
Reduce vulnerabilities
COVID 19 diseases
Influenza H1N1
Subjects
  1. Vergara-Alert, J., van den Brand, J. M., Widagdo, W., & Muñoz, M. (2017). Livestock susceptibility to infection with Middle East respiratory syndrome coronavirus. Emerging infectious diseases, 23(2), 232.
  2. Lo, I. L., Lio, C. F., Cheong, H. H., Lei, C. I., Cheong, T. H., Zhong, X., . . . Sin, N. N. (2020). Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. International journal of biological sciences, 16(10), 1698.
  3. Fullen, D. J., Noulin, N., Catchpole, A., Fathi, H., Murray, E. J., Mann, A., . . . Gilbert, A. (2016). Accelerating influenza research: Vaccines, antivirals, immunomodulators and monoclonal antibodies. The manufacture of a new wild-type H3N2 virus for the human viral challenge model. PLoS One, 11(1), e0145902.
  4. Boopathi, S., Poma, A. B., & Kolandaivel, P. (2020). Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. Journal of Biomolecular Structure and Dynamics, 1-10.
  5. Bai, Y., Yao, L., Wei, T., Tian, F., Jin, D.-Y., Chen, L., & Wang, M. (2020). Presumed asymptomatic carrier transmission of COVID-19. Jama, 323(14), 1406-1407.
  6. Cohen, J., & Kupferschmidt, K. (2020). Countries test tactics in ‘war’against COVID-19: American Association for the Advancement of Science.
  7. Gallo, O., Locatello, L. G., Mazzoni, A., Novelli, L., & Annunziato, F. (2020). The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal immunology, 1-12.
  8. Slater, T., Sawyer, B., & Sträuli, U. (1963). Studies on succinate-tetrazolium reductase systems: III. Points of coupling of four different tetrazolium salts III. Points of coupling of four different tetrazolium salts. Biochimica et biophysica acta, 77, 383-393.
  9. Hazary, R., Chaudhuri, D., & Wishart, G. (2001). Application of an MTT reduction assay for assessing sperm quality and predicting fertilising ability of domestic fowl semen. British Poultry Science, 42(1), 115-117.
  10. Gerdil, C., & Saluzzo, J.-F. (2005). Titration method for a complex viral composition: Google Patents.
  11. Long, B. C., Goldberg, T. L., Swenson, S. L., Erickson, G., & Scherba, G. (2004). Adaptation and Limitations of Established Hemagglutination Inhibition Assays for the Detection of Porcine Anti—Swine Influenza Virus H1N2 Antibodies. Journal of Veterinary Diagnostic Investigation, 16(4), 264-270.
  12. White, J. M., Delos, S. E., Brecher, M., & Schornberg, K. (2008). Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Critical reviews in biochemistry and molecular biology, 43(3), 189-219.
  13. Bianchi, M., Benvenuto, D., Giovanetti, M., Angeletti, S., Ciccozzi, M., & Pascarella, S. (2020). Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics? BioMed Research International, 2020.
  14. Venkatagopalan, P., Daskalova, S. M., Lopez, L. A., Dolezal, K. A., & Hogue, B. G. (2015). Coronavirus envelope (E) protein remains at the site of assembly. Virology, 478, 75-85.
  15. Dimitrov, D. (2004). Virus entry: molecular mechanisms and biomedical applications. Nature Reviews Microbiology, 2(2), 109-122.
  16. Machado, C., & Gutierrez, J. V. (2020). Anosmia and ageusia as initial or unique symptoms after sars-cov-2 virus infection.
  17. Dorigatti, I., Okell, L., Cori, A., Imai, N., Baguelin, M., Bhatia, S., . . . FitzJohn, R. (2020). Report 4: severity of 2019-novel coronavirus (nCoV). Imperial College London, London.
  18. Tavakoli, A., Vahdat, K., & Keshavarz, M. (2020). Novel coronavirus disease 2019 (COVID-19): an emerging infectious disease in the 21st century. ISMJ, 22(6), 432-450.
  19. Pollock, J. J., & Docherty, J. J. (1993). Antiviral composition and method: Google Patents.
  20. Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., . . . Nitsche, (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell.
  21. Kargar Kheirabad, A. (2019). Ammonium Chloride as a Potential Candidate for the Treatment and Controlling of Covid-19. مجله ویروس شناسی ایران, 13(2) , 0-0.
  22. Debnath, U., Dewaker, V., Prabhakar, Y. S., Bhattacharyya, P., & Mandal, A. (2020). Conformational perturbation of SARS-CoV-2 Spike protein using N-acetyl cysteine, a molecular scissor: A probable strategy to combat COVID-19. Preprint.
Emergency Management
Volume 10, Corona Special List
January 2022
Pages 5-14

  • Receive Date 09 May 2021
  • Revise Date 09 January 2022
  • Accept Date 17 July 2021